Lung Cancer Clinical Trial
Official title:
A Study of the Interaction Between Tumor Susceptibility Gene GNMT and Lung Cancer
Environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) were reviewed as
the major risk factors for lung cancer development. In this proposal, the investigators
collected fifteen kinds of major PAHs and the investigators would like to perform the
following studies:
1. Study the gene expression and subcellular localization of GNMT in the normal-tumor
tissue pairs of lung cancer patients.
2. Study the associations of the polymorphisms of GNMT in lung cancer patients and the
susceptibility to lung cancer;
3. To assess the allelic loss at GNMT and determined the LOH rate of GNMT in the
normal-tumor tissue pairs of lung cancer patients.
4. Study the associations of the copy number variation (CNV) of GNMT and the
susceptibility to lung cancer;
5. Study the interaction between GNMT and polycyclic aromatic hydrocarbons (PAHs) in lung
cancer cell lines.
Multi-functional protein Glycine N-methyltransferase (GNMT, EC2.1.1.20, localized to
chromosome 6p12), affects genetic stability by a) regulating the ratio of
S-adenosylmethionine (SAM) to S-adenosylhomocystine (SAH) and b) binding to folate. Based on
the following observations, GNMT is classified as a tumor susceptibility gene: a) diminished
GNMT expression levels in both human hepatocellular carcinoma (HCC) cell lines and tissues;
b) genotypic analyses of several human GNMT gene polymorphisms showed a loss of
heterozygosity in 36-47% of the genetic markers in HCC tissues and also related to the
susceptibility of prostate cancer; c) GNMT binds to environmental carcinogens such as
benzo(a)pyrene (BaP) and aflatoxin B1 (AFB1) and protect the liver cells by inhibiting
DNA-adduct formation.
Environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) were reviewed as
the major risk factors for lung cancer development. In this proposal, the investigators
collected fifteen kinds of major PAHs and would like to perform the following studies:
1. Study the gene expression and subcellular localization of GNMT in the normal-tumor
tissue pairs of lung cancer patients.
2. Study the associations of the polymorphisms of GNMT in lung cancer patients and the
susceptibility to lung cancer;
3. To assess the allelic loss at GNMT and determined the LOH rate of GNMT in the
normal-tumor tissue pairs of lung cancer patients.
4. Study the associations of the copy number variation (CNV) of GNMT and the
susceptibility to lung cancer;
5. Study the interaction between GNMT and polycyclic aromatic hydrocarbons (PAHs) in lung
cancer cell lines.
So far, the investigators have analyzed the gene expression of GNMT in the normal-tumor
tissue pairs of some lung cancer patients. The investigators also analyzed the interaction
between the GNMT and some PAHs using lung cancer cell lines. These data are helpful to
clarify the susceptibility of lung cancer patients with the gene expression in GNMT.
This study is helpful in elucidating the role of GNMT plays in the tumorigenesis of lung
cancer which may have important implications in the development of strategies for the
prevention, diagnosis and treatment of lung cancer and other types of cancer.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|